iBio (NASDAQ:IBIO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of iBio (NASDAQ:IBIO – Free Report) from a sell rating to a hold rating in a report released on Saturday morning,Wall Street Zen reports.

Other equities analysts also recently issued reports about the stock. HC Wainwright started coverage on shares of iBio in a report on Thursday, September 17th. They set a “buy” rating and a $7.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of iBio in a report on Monday, September 21st. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $6.00.

Check Out Our Latest Stock Analysis on iBio

iBio Trading Down 3.4%

IBIO stock opened at $0.71 on Friday. The firm has a 50 day moving average of $0.97 and a 200-day moving average of $1.62. iBio has a 12-month low of $0.68 and a 12-month high of $3.82. The company has a market cap of $49.79 million, a price-to-earnings ratio of -2.52 and a beta of 1.47.

iBio (NASDAQ:IBIO – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. The firm had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $0.03 million. Sell-side analysts forecast that iBio will post -0.35 earnings per share for the current fiscal year.

Institutional Trading of iBio

Institutional investors and hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC purchased a new stake in iBio during the 2nd quarter worth about $873,000. Affinity Asset Advisors LLC lifted its holdings in iBio by 51.0% in the 1st quarter. Affinity Asset Advisors LLC now owns 3,107,200 shares of the company’s stock valued at $5,904,000 after purchasing an additional 1,050,000 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in iBio in the 3rd quarter valued at about $105,000. R Squared Ltd purchased a new position in iBio in the 3rd quarter valued at about $29,000. Finally, Walleye Capital LLC lifted its holdings in iBio by 95.9% in the 1st quarter. Walleye Capital LLC now owns 388,554 shares of the company’s stock valued at $738,000 after purchasing an additional 190,179 shares in the last quarter. 7.90% of the stock is currently owned by hedge funds and other institutional investors.

About iBio

(Get Free Report)

iBio, Inc. is a biotechnology company focused on using artificial intelligence and other computational tools to discover and develop therapies. Its research has included programs targeting obesity and metabolic diseases, as well as oncology. The company’s current approach builds on its earlier work in biologics manufacturing. Historically, iBio used its plant-based FastPharming platform to produce proteins and antibodies for research and therapeutic development. iBio is based in the United States and has shifted its focus from plant-based biologics production toward AI-enabled drug discovery.

Further Reading

Analyst Recommendations for iBio (NASDAQ:IBIO)

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.